Phosphagenics seeks listing on UK's AIM
Wednesday, 26 May, 2004
Melbourne-based Phosphagenics (ASX:POH) -– formerly Vital Capital -– has flagged its intention to seek a dual listing on the London Stock Exchange's Alternative Investment Market (AIM).
The company said in a statement that it believes the listing will provide access to a more developed capital market for the company’s globally orientated healthcare products
Investment bank Williams de Broë has been appointed as nominated adviser and stockbroker for the dual listing process.
Phosphagenics last month announced the successful completion of animal studies for its transdermal delivery system for morphine. The system uses d-alpha tocopherol combined with a phosophate molecule to create an enhanced form of Vitamin E which carries morphine across the dermis.
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
